Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UCB Major Shareholding Notification 2022

May 25, 2022

4017_mrq_2022-05-25_516da530-93e0-44cb-839a-81147474dca2.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

Transparency notification FMR LLC

Brussels (Belgium), 25 May 2022 – 20:00 (CEST)Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 24 May 2022.

FMR LLC., notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold on 18 May 2022.

On 18 May 2022, FMR LLC. (taking into account the holding of its affiliates) owned 9 763 725 UCB shares with voting rights, representing 5.02% of the total number of shares issued by the company (194 505 658), versus 4.99% (9 714 254 UCB shares) in the previous notification dated 23 May 2022.

2. Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:
Name Address (for legal entities)
FMR LLC The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County,
Delaware, 19801.
  • Date on which the threshold is crossed: 18 May 2022.
  • Threshold crossed (in %): 5%.
  • Denominator: 194 505 658.

Notified details:

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
FMR LLC 0 0 0,00%
FIAM LLC 863.989 868.189 0,45%
Fidelity Institutional Asset Management
Trust Company
448.349 455.749 0,23%
Fidelity Management & Research
Company LLC
7.433.517 7.472.126 3,84%
Fidelity Management Trust Company 616.056 616.056 0,32%
FMR Investment Management (UK)
Limited
180.200 180.200 0,09%
Strategic Advisers LLC 172.143 171.405 0,09%
Subtotal 9.714.254 9.763.725 5,02%
TOTAL 9.763.725 0 5,02% 0,00%
B) Equivalent financial instruments After the transaction
Holders of equivalent
financial instruments
Type of financial instrument Expiration date Exercise period or
date
# of voting rights
that may be
acquired if the
instrument is
exercised
% of voting rights Settlement
TOTAL 0 0,00%
TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 9.763.725 5,02%

Chain of controlled undertakings through which the holding is effectively held:

Fidelity Institutional Asset Management Trust Company and FIAM LLC are controlled by FIAM Holdings LLC, FIAM Holdings LLC is controlled by FMR LLC Fidelity Management Trust Company is controlled by FMR LLC Fidelity Management & Research Company LLC is controlled by FMR LLC FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC Strategic Advisers LLC is controlled by Fidelity Advisory Holdings LLC Fidelity Advisory Holdings LLC is controlled by FMR LLC FMR LLC is not a controlled entity.

Additional information: The holdings attributed to the entities mentioned in heading 10 arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited and Strategic Advisers LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

For further information, contact UCB:

Investor Relations Antje Witte T +32 2 559 94 14 [email protected]

Corporate Communications Laurent Schots T+32 2 559 92 64 [email protected]

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news